Journals / Türk Nöroloji Dergisi / 2009 / Cilt: 15 - Sayı: 3

Development of multiple sclerosis in patients with optic neuritis: Analysis of predictive factors

Optik nöritli hastalarda multipl skleroz gelişimi: Öngörücü etmenlerin analizi

Pages
119–123
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our results might aid patient selection for early treatment and the determination of prognosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Optic neuritis (ON) is inflammation of the optic nerve that generally leads to transient loss of vision.
📊
Key Findings & Data:METHODS: Medical charts of patients followed-up at Istanbul University, Faculty of Medicine, Department of Neurology between 1987 and 2003 were screened for patients with isolated ON at first presentation.
💡
Conclusion & Impact:Our results might aid patient selection for early treatment and the determination of prognosis.
🔬Design:Modeling & Simulation
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Optic neuritis (ON) is inflammation of the optic nerve that generally leads to transient loss of vision. Unilateral optic neuritis is quite common upon first presentation in multiple sclerosis (MS) patients, but it may also remain as a clinically isolated syndrome. In this study we aimed to determine what factors are associated with the development of MS in isolated ON patients. METHODS: Medical charts of patients followed-up at Istanbul University, Faculty of Medicine, Department of Neurology between 1987 and 2003 were screened for patients with isolated ON at first presentation. A cohort of 90 patients was thusly obtained. Clinical and demographic features, visual evoked potential, cerebrospinal fluid (CSF), and magnetic resonance imaging findings, and time to definitive MS according to McDonald’s criteria were recorded. RESULTS: In all, 50% of the patients developed definitive MS after 13 months (95% CI: 4.4-19.6). Two of the patients developed neuromyelitis optica during the course of their follow-up. The development of MS was significantly associated with the presence of a T2 lesion (p= 0.001), oligoclonal bands (OCBs) in the CSF (p= 0.002), absence of papilledema (p= 0.027), absence of severe visual impairment (p= 0.016), and subacute (> 1 day) visual impairment (p= 0.005), as per log rank testing. According to the Cox proportional hazard regression model, the presence of a T2 lesion (hazard ratio: 4.8; 95% CI: 1.5-15.4) and OCBs (hazard ratio: 3.6; 95% CI: 1.1-11.5) are strongly predictive of the progression to MS. CONCLUSION: As some previous studies have noted, the risk of developing MS after ON is significantly higher in the presence of a T2 lesion and OCBs in the CSF. We think that this should be taken into account before starting early treatment for MS. Recent studies on the pathogenesis of MS have suggested that early treatment of MS reduces neurological disability in the long term. Our results might aid patient selection for early treatment and the determination of prognosis.

Özet

AMAÇ: Optik nörit (ON), optik sinirin çoğunlukla geçici görme kaybına neden olan inflamasyonudur. Tek taraflı ON, multipl skleroz (MS)’un sık görülen başlangıç bulgusudur; ancak klinik izole sendrom (KİS) olarak kalabilmektedir. Bu çalışmada, izole ON geliştiren hastaların MS’e dönüşmesi ile ilişkili faktörlerin tanımlanması amaçlanmıştır. YÖNTEMLER: İstanbul Tıp Fakültesi Nöroloji Anabilim Dalı, Multipl Skleroz Birimi Polikliniğinde 1987-2003 yılları arasında görülen 2836 hastanın dosyası gözden geçirilmiş ve ilk başvuruda, ON tanısı alan 90 hasta (61 kadın, 29 erkek) 2008 yılında birimimize davet edilerek, yeniden değerlendirilmiştir. Klinik ve demografik özellikler, görsel uyarılmış potansiyeller, beyin omurilik sıvısının (BOS) özelikleri, manyetik rezonans görüntüleme (MRG) incelemeleri ve McDonald kriterlerine göre MS’e dönüşme tarihi tekrar gözden geçirilmiştir. BULGULAR: ON’un ortalama başlangıç yaşı 109 ± 82 aydı. MS’e dönüşen hastaların %50’sinin 13 ay içinde (%95 güven aralığı; 4.4-19.6) kesin MS geliştirdiği gözlendi. Yirmi dokuz erkek hastanın dokuzu, 61 kadın hastanın altısı bilateral ON ile başvurdu (ki-kare; p= 0.012). İki hastanın izlemi sırasında nöromiyelitis optika gelişti. MS geliştirme riskinin T2/Flair lezyonlarının varlığı (p= 0.001), BOS’ta oligoklonal bandlar (OKB)’ın saptanması (p= 0.002), papilödem olmaması (p= 0.027), ileri düzeyde görsel kaybın olmaması (p= 0.016) ve görsel kaybın subakut (> 1 gün) gelişmesi (p= 0.005) ile anlamlı olarak arttığı belirlendi (log-rank testi). Cox orantılı hazard regresyon modeline göre incelenen parametrelerden MS’e dönüşümü en iyi şekilde öngören etmenlerin T2/Flair lezyonunun (hazard oranı 4.8, %95 güven aralığı 1.5-15.4) veya OKB’nin (hazard oranı 3.6, %95 güven aralığı 1.1-11.5) varlığı olduğu bulundu. SONUÇ: Daha önceki çalışmalarda da belirtildiği gibi, T2 lezyonu ve BOS’ta OKB saptanması durumunda MS geliştirme riski belirgin derecede fazladır. Son zamanlarda MS patogenezinin erken dönemlerini daha iyi anlamamızı sağlayan çalışmalar, MS tedavisine erken başlamanın aksonal hasarı ve uzun dönemde nörolojik sekeli azaltmak gibi fayda sağlayacağına yönelik tartışmalar başlatmıştır. Bu sonuçların göz önünde bulundurulması erken tedavi için hasta seçimi ve prognozun belirlenmesi bakımından yol gösterici olabilir.

🔖

Cite This Article

AKALIN, B., DURMUŞ, H., ERAKSOY, M., KÜRTÜNCÜ, M., TÜZÜN, E., MUTLU, M., DEMİR, G. A. (2022). Development of multiple sclerosis in patients with optic neuritis: Analysis of predictive factors. Türk Nöroloji Dergisi, Cilt: 15 - Sayı: 3, 119–123. https://ajindex.com/articles/637036

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Rodriguez M, Siva A, Cross SA, O'Brien PC, Kurland LT. Optic neuritis: A population-based study in Olmsted County, Minnesota. Neurology 1995;45:244-50
  2. Ebers GC. Optic neuritis and multiple sclerosis. Arch Neurol 1985;42:702-4
  3. Bjartmar C, Kinkel PR, Kidd G, Rudick RA, Trapp BD. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 2001;57:1248-52
  4. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Brück W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000;123:1174-83
  5. Coyle PK. Early treatment of multiple sclerosis to prevent neurologic damage. Neurology 2008;71(24 Suppl 3):3-7
  6. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-52
  7. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurology 2001;50:121-7
  8. Paolillo A, Pozzilli C, Gasperini C, Giugni E, Mainero C, Giuliani S, et al. Brain atrophy in relapsing-remitting multiple sclerosis: Relationship with ‘black holes’, disease duration and clinical disability. J Neurol Sci 2000;174:85-91
  9. Fisher E, Rudick RA, Cutter G, Baier M, Miller D, WeinstockGuttman B, et al. Relationship between brain atrophy and disability: An 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000;6:373-7
  10. Tanja K, Gueanelle L, Andreas B, Jana S, Wolfgang B. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202-12
  11. De Stefano N, Filippi M. MR spectroscopy in multiple sclerosis. J Neuroimaging 2007;17(Suppl 1):31-5
  12. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-97
  13. Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neuro 2002;51:481-90
  14. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 1997;49:1404-13
  15. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: Final optic neuritis t